The UK and US have hammered out a important trade agreement that will ensure no levies on UK drug products being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to raise funding on medicines through the NHS. This commitment ensures that tariffs on these key exports will remain at nothing for a period of three years.
This deal comes after earlier warnings to dramatically increase tariffs on branded drug imports, with increases discussed up to one hundred percent.
"This agreement between the United Kingdom reinforces the international landscape for innovative medicines and brings long-overdue equity to transatlantic drug exports," an announcement noted.
Commercial Importance
Drugs constitute one of the Britain's most significant goods shipped to the United States, which is by far the primary buyer for large UK drugmakers.
Statistics reveal that in the 12 months leading up to last September, the UK sold medicines totaling £11.1bn to the US. This amount represented 17.4% of all goods exports in that period.
"This deal safeguards jobs, boosts capital expenditure and sets the stage for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Specific NHS Changes
The pact includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be capped at 15%. In the past, rebates exceeded 20%.
Recent Tensions
The deal takes place against a protracted tension between the drug companies and the UK government over drug pricing and approval rates.
This friction were intensified by assertions that American patients were paying a premium for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been delayed or cancelled, while major investments have been pledged toward American operations.
The Science Minister stated that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the last ten years.
